https://ddn.pluspedia.org/w/index.php?action=history&feed=atom&title=Heparin 2026-11-04T11:32:45Z Versionsgeschichte dieser Seite in PlusPedia MediaWiki 1.43.3 https://ddn.pluspedia.org/w/index.php?title=Heparin&diff=40450&oldid=prev 2010-04-03T16:51:22Z

<p>Die Seite wurde neu angelegt: „<a href="/wiki/Datei:Pptpdtjpg1.png" title="Datei:Pptpdtjpg1.png">miniatur|Entstehender Artikel</a> {| class=&quot;wikitable&quot; | | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Siehe auch&#039;&#039;&#039; | align=&quot;left&quot; width=&quot;800&quot; | |- | bgcolor=&quot;#d…“</p> <p><b>Neue Seite</b></p><div>[[Datei:pptpdtjpg1.png|miniatur|Entstehender Artikel]]<br /> {| class=&quot;wikitable&quot; |<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Siehe auch&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot; |<br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Freie Übersichtsartikel&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot; |&lt;ref name=&quot;PMID11053011&quot;&gt;Structural determinants of antiproliferative activity of heparin on pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 279(5):L779-89 (2000) PMID 11053011 &lt;/ref&gt;&lt;ref name=&quot;PMID11451734&quot;&gt;Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol 21(7):1094-6 (2001) PMID 11451734 &lt;/ref&gt;&lt;ref name=&quot;PMID371632&quot;&gt;Heparin: new concepts relevant to clinical use. Blood 53(4):525-44 (1979) PMID 371632 &lt;/ref&gt;&lt;ref name=&quot;PMID11157643&quot;&gt;Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119(1 Suppl):64S-94S (2001) PMID 11157643 &lt;/ref&gt;&lt;ref name=&quot;PMID10334162&quot;&gt;Clinical uses of low-molecular-weight heparins. Chest 115(5):1418-23 (1999) PMID 10334162 &lt;/ref&gt;&lt;ref name=&quot;PMID9822059&quot;&gt;Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 114(5 Suppl):489S-510S (1998) PMID 9822059 &lt;/ref&gt;&lt;ref name=&quot;PMID1327666&quot;&gt;Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 102(4 Suppl):337S-351S (1992) PMID 1327666 &lt;/ref&gt;&lt;ref name=&quot;PMID11413093&quot;&gt;Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. Circulation 103(24):2994-3018 (2001) PMID 11413093 &lt;/ref&gt;&lt;ref name=&quot;PMID18227486&quot;&gt;Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin. Diabetes Care 31 Suppl 2():S202-7 (2008) PMID 18227486 &lt;/ref&gt;&lt;ref name=&quot;PMID12091128&quot;&gt;Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics. Haematologica 87(7):757-70 (2002) PMID 12091128 &lt;/ref&gt;&lt;ref name=&quot;PMID16030035&quot;&gt;The heparins: all a nephrologist should know. Nephrol Dial Transplant 20(10):2036-42 (2005) PMID 16030035 &lt;/ref&gt;&lt;ref name=&quot;PMID10193791&quot;&gt;Therapeutic uses of heparinoids in renal disease patients. Nephrol Dial Transplant 14(3):540-3 (1999) PMID 10193791 &lt;/ref&gt;&lt;ref name=&quot;PMID19685350&quot;&gt;Low-molecular-weight heparin in patients with renal insufficiency. Swiss Med Wkly 139(31-32):438-52 (2009) PMID 19685350 &lt;/ref&gt;&lt;ref name=&quot;PMID7090372&quot;&gt;The risks and benefits of heparin therapy. West J Med 136(3):241-2 (1982) PMID 7090372 &lt;/ref&gt;&lt;ref name=&quot;PMID7783398&quot;&gt;Heparin lowers blood pressure: biological and clinical perspectives. Kidney Int 47(4):1017-22 (1995) PMID 7783398 &lt;/ref&gt;<br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Wichtige Übersichtsartikel&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Medline Suchterm/ Synonyme&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#00dfdf&quot; | &#039;&#039;&#039;Was ist das&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Struktur&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Physiologie&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Knockout&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Transgen&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Mutation&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Polymorphismus&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Genexpression&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Inhibitoren&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |-<br /> | bgcolor=&quot;#dfdfdf&quot; | &#039;&#039;&#039;Agonisten&#039;&#039;&#039;<br /> | align=&quot;left&quot; width=&quot;800&quot;| <br /> |}<br /> <br /> ----<br /> <br /> == Bibliographie ==<br /> &lt;references /&gt;<br /> <br /> <br /> {{LinkWP_Miniartikel|Txt=Heparin|Link=Heparin}}</div>

Ossip Groth